Regulatory Risk To Aurobindo Pharma’s Business

Regulatory Risk To Aurobindo Pharma’s Business

 Click Here to Watch Video

Shares of Aurobindo Pharma have declined nearly 40% so far this year, it’s worst performance since 2011, on the back of regulatory problems in U.S., its largest market.